Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...
IDH’s operations network extends beyond Egypt to Jordan, Sudan, and Nigeria. As of December 2022, IDH had 552 lab branches, up by 50 branches compared to 2021. It completed 32.7 million tests in 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback